Ken Griffin Poseida Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$2.7 - $4.04 $29,970 - $44,844	11,100 Added 100.0%	22,200 $63,000
Q2 2024 Aug 14, 2024	BUY	$2.0 - $3.46 $11,000 - $19,030	5,500 Added 98.21%	11,100 $32,000
Q1 2024 May 15, 2024	BUY	$2.76 - $4.13 $15,455 - $23,128	5,600 New	5,600 $17,000
Q3 2023 Nov 14, 2023	SELL	$1.62 - $2.79 $14,094 - $24,273	-8,700 Reduced 43.5%	11,300 $26,000
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.4 $24,070 - $49,300	14,500 Added 263.64%	20,000 $35,000
Q1 2023 May 15, 2023	SELL	$3.08 - $8.73 $45,584 - $129,204	-14,800 Reduced 72.91%	5,500 $16,000
Q4 2022 Feb 14, 2023	BUY	$3.33 - $6.38 $67,599 - $129,514	20,300 New	20,300 $107,000

38.5M

377K

22.2K

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $234M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.